Education
About Us
Working with TipRanks
Follow Us
Outlook Therapeutics (OTLK)
NASDAQ:OTLK
OTLK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.87 - $9.98
Previous CloseN/A
Volume358.39K
Average Volume (3M)415.82K
Market Cap
$39.14M
Enterprise Value$71.13M
Total Cash (Recent Filing)$10.81M
Total Debt (Recent Filing)$15.49M
Price to Earnings (P/E)―
Beta-0.43
Next Earnings
May 14, 2025EPS Estimate
-0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.94
Shares Outstanding32,620,180
10 Day Avg. Volume443,911
30 Day Avg. Volume415,817
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap1.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda7.36
Forecast
1Y Price Target
$10.00Price Target Upside777.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Outlook Therapeutics News
PremiumCompany Announcements
Outlook Therapeutics Issues Convertible Note to Avondale
---
Bulls Say, Bears Say
Bulls Say
Market PotentialThe current valuation is seen as attractive, representing significant upside potential if the FDA approves ONS-5010.
Regulatory ApprovalThe FDA agreed to the Special Protocol Assessment for additional trials, indicating a path forward for BLA approval.
Strategic CollaborationOutlook has entered into a strategic collaboration with Cencora to support the global commercial launch of Lytenava.
Bears Say
Clinical Trial ResultsONS-5010 missed the primary endpoint of non-inferiority at week 8 set forth in the special protocol assessment with the FDA.
Development Program RiskONS-5010 is the company's sole active development program.
Regulatory UncertaintyIt remains unclear how much weight the FDA will place on the finding of non-inferiority margin at week 12, as the 8-week readout was the only preset endpoint of the NORSE 8 study.
---
Ownership Overview
27.93% Insiders
4.05% Mutual Funds
1.35% Other Institutional Investors
62.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OTLK FAQ
What was Outlook Therapeutics’s price range in the past 12 months?
Outlook Therapeutics lowest stock price was $0.87 and its highest was $9.98 in the past 12 months.
What is Outlook Therapeutics’s market cap?
Outlook Therapeutics’s market cap is $39.14M.
When is Outlook Therapeutics’s upcoming earnings report date?
Outlook Therapeutics’s upcoming earnings report date is May 14, 2025 which is in 36 days.
How were Outlook Therapeutics’s earnings last quarter?
Outlook Therapeutics released its earnings results on Feb 14, 2025. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.76 by -$0.13.
Is Outlook Therapeutics overvalued?
According to Wall Street analysts Outlook Therapeutics’s price is currently Undervalued.
Does Outlook Therapeutics pay dividends?
Outlook Therapeutics does not currently pay dividends.
What is Outlook Therapeutics’s EPS estimate?
Outlook Therapeutics’s EPS estimate is -0.54.
How many shares outstanding does Outlook Therapeutics have?
Outlook Therapeutics has 32,620,180 shares outstanding.
What happened to Outlook Therapeutics’s price movement after its last earnings report?
Outlook Therapeutics reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.76. Following the earnings report the stock price went up 1.63%.
Which hedge fund is a major shareholder of Outlook Therapeutics?
Currently, no hedge funds are holding shares in OTLK
---
Outlook Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.00 (777.19% Upside)
$10.00 (777.19% Upside)
Blogger Sentiment
Bullish
OTLK Sentiment 100%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.39%
12-Months-Change
Fundamentals
Return on Equity
<0.01%
Trailing 12-Months
Asset Growth
-21.58%
Trailing 12-Months
Company Description
Outlook Therapeutics
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
---
OTLK Stock 12 Month Forecast
Average Price Target
$10.00
▲(777.19% Upside)
Technical Analysis
X4 Pharmaceuticals
―
Iterum Therapeutics
―
Celularity
―
Century Therapeutics
―
AN2 Therapeutics, Inc.
―
Best Analysts Covering OTLK
1 Year
1 Year Success Rate
1/20 ratings generated profit
1 Year Average Return
-52.84%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 5.00% of your transactions generating a profit, with an average return of -52.84% per trade.
---